Article ; Online: Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.
Journal of cancer research and clinical oncology
2018 Volume 144, Issue 3, Page(s) 519–529
Abstract: Purpose: Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, ... ...
| Abstract | Purpose: Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, osteopontin (OPN) and fibronectin (FN) correlate with the response to neo-adjuvant CHT (naCHT) in children with advanced inoperable MPNST. Methods: The study included 26 children with MPNST (M/F 14/12, median age 130 months) treated in Polish centers of pediatric oncology between 1992 and 2013. Tissue expression of markers was studied immunohistochemically in the manually performed tissue microarrays and assessed semi-quantitatively as low and high, based on the rate of positive cells and staining intensity. Results: Good response to naCHT was noted in 47.6%, while poor-in 52.4% of patients. The response to naCHT was influenced negatively by the presence of neurofibromatosis NF1 and high initial tumor tissue expression of OPN, survivin, p53 and cyclin D1. Patients with high tumor expression of either OPN, survivin or p53 and those with simultaneous high expression of ≥ 3 of the markers, responded significantly worse to naCHT, than patients, in whom expression of ≤ 2 markers were detected at diagnosis. Nearly, 85% of patients expressing ≥ 3 markers, responded poor to CHT; while 87.5% of children, expressing ≤ 2 markers, were good responders. Conclusion: The initial tumor tissue expression of OPN, survivin, p53 and cyclin D1 may serve as markers to predict response to naCHT in pediatric advanced MPNST. Future studies in more numerous group of patients are needed to confirm these preliminary results. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Pharmacological/metabolism ; Biomarkers, Tumor/metabolism ; Child ; Child, Preschool ; Cyclin D1/metabolism ; Cytokines/metabolism ; Disease Progression ; Female ; Humans ; Infant ; Inhibitor of Apoptosis Proteins/metabolism ; Male ; Neoadjuvant Therapy ; Nerve Sheath Neoplasms/diagnosis ; Nerve Sheath Neoplasms/drug therapy ; Nerve Sheath Neoplasms/metabolism ; Nerve Sheath Neoplasms/pathology ; Neurilemmoma/drug therapy ; Neurilemmoma/metabolism ; Neurilemmoma/pathology ; Osteopontin/metabolism ; Prognosis ; Treatment Outcome | |||||
| Chemical Substances | BIRC5 protein, human ; Biomarkers, Pharmacological ; Biomarkers, Tumor ; CCND1 protein, human ; Cytokines ; FN1 protein, human ; Inhibitor of Apoptosis Proteins ; SPP1 protein, human ; Osteopontin (106441-73-0) ; Cyclin D1 (136601-57-5) | |||||
| Language | English | |||||
| Publishing date | 2018-03 | |||||
| Publishing country | Germany | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 134792-5 | |||||
| ISSN | 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382 | |||||
| ISSN (online) | 1432-1335 | |||||
| ISSN | 0171-5216 ; 0084-5353 ; 0943-9382 | |||||
| DOI | 10.1007/s00432-018-2580-1 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.10: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.